TP53 and myelodysplastic syndrome: The discrepancy between WHO-5 and ICC emphasizes this issue: the former considers MDS with 0–19% BM/PB blasts as a homogenous group, mandating the demonstration of biallelic TP53 inactivation regardless of blast percentage.